Section Arrow
Quote
APLS.NASDAQ
- Apellis Pharmaceuticals
Quotes are at least 15-min delayed:2026/05/04 16:42 EDT
After Hours
Last
 40.94
-0.03 (-0.07%)
Bid
40.96
Ask
40.98
High 40.97 
Low 40.94 
Volume 3.63K 
Regular Hours (Closed)
Last
 40.97
+0.01 (+0.02%)
Day High 
40.97 
Prev. Close
40.96 
1-M High
41 
Volume 
2.52M 
Bid
40.96
Ask
40.98
Day Low
40.94 
Open
40.955 
1-M Low
40.35 
Market Cap 
5.24B 
Currency 美元 
P/E 227.56 
%Yield -- 
10-SMA 40.95 
20-SMA 40.86 
50-SMA 29.23 
52-W High 41 
52-W Low 16.1 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.18/-0.69
Enterprise Value
5.62B
Balance Sheet
Book Value Per Share
2.89
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
1.00B
Operating Revenue Per Share
2.13
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
LNAILunai Bioworks Inc.0.3246+0.0047+1.47%-- 
After Hours 0.293 -0.0316 -9.74%
SGMOSangamo Therapeutics0.1776+0.0426+31.56%-- 
After Hours 0.1756 -0.002 -1.13%
CNSPCNS Pharmaceuticals Inc7.84+5.5289+239.23%0PE
After Hours 7.43 -0.41 -5.23%
CABACabaletta Bio3.83+0.89+30.27%-- 
After Hours 3.7224 -0.1076 -2.81%
IOVAIovance Biotherapeutics3.85+0.45+13.24%-- 
After Hours 3.84 -0.01 -0.26%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.